GET A PIECE OF TURN THERAPEUTICS
Bradley Burnam • Chief Executive Officer, Board Member & Founder
Read More
Dr. Neil Ghodadra, M.D. • Chief Medical Officer & Board Member
Read More
Abraham Chesed • Board Member
Read More
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Bonus shares for this offering are capped at 20%
Voting Proxy
(a) The Subscriber hereby appoints the Chief Executive Officer of the Company (the “Chief Executive Officer”), or his or her successor as Chief Executive Officer, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution to assign this proxy to any officer or director, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the Chief Executive Officer determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the Chief Executive Officer for the accomplishment of the foregoing. See Offering Circular for complete information.
Investment Incentives & Bonuses*
Loyalty Bonus | 3% Bonus Shares
Investors who have previously, in a prior offering, invested in the Company, receive 3% Bonus Shares (the “Loyalty Bonus”), in addition to any StartEngine Venture Club Bonus shares, or Amount-Based Bonus shares, to which they are entitled to receive.
Amount-Based Bonus
Tier 1: Invest $5,000+ and receive 3% bonus shares.
Tier 2: Invest $10,000+ and receive 5% bonus shares.
Tier 3: Invest $25,000+ and receive 7% bonus shares.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.
The 10% StartEngine Venture Club Bonus
GLOBAL HEALTH SOLUTIONS, INC. , dba Turn Therapeutics will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $11.26 / share, you will receive 110 shares of Common Stock, meaning you’ll own 110 shares for $1126. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus in addition to the aforementioned bonus, provided that the maximum bonus shares granted to any investor shall not be greater than 20%.
05.30.25
“This solves a massive problem. If that happened to me, there would be no price that would matter.” - Kevin O’Leary
When Mr. Wonderful says “Let’s talk after this,” you know you’ve struck a chord.
During the livestream, Kevin revealed his personal struggles with toenail fungus, calling it “extremely hard to cure.” He’s tried what's on the market. And he is not alone: over 10% of the planet struggles with toenail fungus.
The science behind the tech is simple, yet powerful. Our patented, FDA-cleared technology is oil-based and proven to go where others can’t get: beneath the nail.
Kevin O’Leary called Turn Therapeutics a company that could “create tremendous shareholder value,” with Bradley’s authentic mission, proven results, large markets, and the executional leadership to scale it.
Kevin isn’t just impressed, he wants a sit down meeting to discuss getting involved with Turn Therapeutics. You can watch the full livestream here.
Join us now before the momentum takes off.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Kevin O’Leary is a paid spokesperson for StartEngine. See his 17(b) disclosure, here. Kevin O'Leary is not endorsing Turn Therapeutics as an investment in this webinar; he is merely expressing his private opinion while interviewing companies funding on StartEngine.
05.27.25
Going public is a milestone—but it shouldn’t be the finish line.
For companies that are truly prepared, a public listing can be a powerful step in a long-term growth plan. It’s a chance to scale impact, expand investor access, and create consistent value across broader markets. But when treated as the end goal, it can become a trap—stalling momentum instead of accelerating it.
At Turn Therapeutics, we believe a company should earn the right to be public. To demonstrate that its ongoing programs are worthy of public market capital. To prioritize long-term plans, not just short-term hype. To prove that it will create value for its shareholders, not just flashy headlines.
What You’ll Learn in This Webinar:
🗓 Webinar Date: June 5, 2025
🕞 Time: 3:30PM ET
👉 Register for the Webinar Now
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.25.25
Today we take a moment to honor those who sacrificed their lives for us.
At Turn Therapeutics, our mission is to create safe, effective medicines that challenge conventional limits. So having the opportunity to protect those that protect us brings deep excitement and motivation to our pursuit.
A Major Leap in Vaccine Science
We recently achieved a milestone in vaccine delivery: 100% recovery of live virus with our patented platform, even after 72 hours at room temperature. No refrigeration or freezers used.
This could dramatically change vaccine access in combat zones, rural clinics, and disaster zones. Places where live vaccines with delicate storage requirements were deemed too hard to reach.
What’s Ahead
We are now commencing a study to determine maximum stability at both refrigerated and room temperature. From there, intranasal dosing studies will begin in an effort to develop a version that can be used in humans.
To those who served and sacrificed, thank you.
We remember you in the mission we carry forward.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.25.25
“Frankly, I think this is a very interesting deal, no question about it.”
-Kevin O’Leary
What made Mr. Wonderful (aka Kevin O’Leary) so excited about Turn Therapeutics?
"The best place to catch the waves in these kinds of companies is after they've proven one outcome, and then they're starting to multiply on that outcome... and you've proven you can get one to market. That's a very big deal" - Kevin O’Leary
Key Highlights:
🌟 Kevin was thrilled with our toenail fungus formula after suffering it himself and finding no easy cures.
🌟 He recognized our massive market opportunity ($15B+) and affirmed Bradley’s ability to execute.
🌟 Mr. Wonderful sees a vision for global market distribution, with the goal of enhancing shareholder value over time.
🌟 By the end of the livestream, Kevin wanted to go beyond just a conversation.
Couldn’t join us live? Check out the replay below.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.23.25
We're About to Start with Kevin O’Leary - Join Livestream Now!
Bradley Burnam built Turn Therapeutics after battling a drug-resistant infection and inventing his own cure.
Hop on now as he joins Kevin O’Leary to share Turn’s journey from unlikely to unstoppable—and why he chose to invite everyone to own a piece of his life’s work.
🗓 Friday, May 23
⏰ 12PM ET
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.22.25
TOMORROW, you’ll hear a story that’s rare in biotech—and even rarer in healthcare.
Bradley Burnam didn’t come from a pharma dynasty. He started Turn Therapeutics in his garage, after battling his own drug-resistant infection and taking matters into his own hands. There, a safer, more effective drug delivery platform was invented. 3 FDA clearances and 17 patents later, investors are paying attention.
This Friday, May 23 at 12pm ET, Bradley sits down with Kevin O’Leary (aka Mr. Wonderful) for a live conversation on what Turn has built and why investors, strategics, and media are watching closely.
Here’s why investors are watching:
From wound care and eczema to cold-chain-free vaccines, this is the kind of biotech story that doesn’t come around often. And it’s just getting started.
See you at noon ET tomorrow.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.20.25
Tune in this Friday for a livestream you won’t want to miss.
This week, Turn Therapeutics goes live with Kevin O’Leary to share why our multi-patented drug delivery platform, 3 FDA clearances, and major market segments are drawing big investor attention.
Founder & CEO Bradley Burnam will sit down with Mr. Wonderful to discuss:
This isn’t a pitch—it’s a conversation about where healthcare is headed.
Event Details:
🗓 Friday, May 23
⏰ 12 pm ET
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.16.25
We’re excited to announce an expansion of our capital partnership with global private equity fund, GEM.
This is an expansion of our existing $75M agreement with GEM, increasing their total committed capital to $85M. Under the updated agreement, Turn Therapeutics now has access to an additional up to $10 million in committed capital—available immediately upon going public.
Why This Matters
✅ Up to $10M additional draw on the day of listing.
🚫 No trading volume restrictions— funds are accessible regardless of market activity
🌟 Enhances investor confidence with a stronger cash position at debut
🏦 Demonstrates increased institutional backing, reinforcing the strength of our mission and model
Turn is not just thinking about today. We strategically are planning for needs at every phase of our future to ensure a healthy company with sufficient capital to achieve our intended goals.
Thank you for your continued belief in what we’re building.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.15.25
🚨 Schedule Update - Livestream Moved to May 23 @ 12pm ET
Join Kevin O’Leary (aka Mr. Wonderful) and Turn Therapeutics Founder & CEO Bradley Burnam for a livestream exploring the company's pioneering work, the vision driving its growth, and why investors are paying close attention to this disruptive force in the healthcare industry.
Turn Therapeutics is a biotechnology firm with FDA-cleared products, proprietary delivery platforms, and active engagement across multiple high-value therapeutic markets.
What You’ll Hear
🧬 The science behind Turn’s breakthrough drug delivery technology
🚀 What makes Turn Therapeutics a standout in modern medicine
📈 Why investors and media are paying attention
Bradley Burnam will also share Turn Therapeutics’ progress and why the company’s vision is gaining momentum across multiple health industries.
Ready to see what’s next for healthcare innovation?
Tune in to the livestream May 23 @ 12pm ET.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
05.12.25
💉 Vaccine Delivery Breakthrough
Turn Therapeutics is poised to dramatically simplify the shipping, storage, and administration of vaccines, particularly in remote or low-resource settings.
After achieving 24 hour stability earlier this year, our newest study demonstrated 72 hours of stability with ZERO LOSS of viable vaccine at room temperature. Vaccines such as these typically last 4-6 hours at room temperature. This particular vaccine candidate is intended for troops and citizens in remote regions.
“...a major leap in vaccine science.” -Bradley Burnam, CEO
This milestone brings us closer to a world in which geography is no longer a barrier to life-saving medicines.
✅ Simplified Shipping + Storage = Greater Vaccine Access
Our PermaFusion platform is flexible and scalable. This work brings us one step closer to the next generation of vaccine delivery.
I wonder what will be next in our journey?
To learn more, read the full press release on Business Wire by clicking below.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Members get an extra 10% shares in addition to rewards below!
Venture Club
Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Tier 1
Invest $5,000+ and receive 3% bonus shares.
Tier 2
Invest $10,000+ and receive 5% bonus shares.
Tier 3
Invest $25,000+ and receive 7% bonus shares.
0/2500
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.